Improving Lives After Lung Transplant

---

Canvas Pharmaceuticals is developing Tacrolimus Inhalation Powder for prevention of acute rejection and maintenance of lung allograft in lung transplant patients to drive efficacy and decrease toxicities compared to standard of care oral tacrolimus. 

Tacrolimus Inhalation Powder is a novel, patented dry powder formulation of tacrolimus delivered via an easy-to-use dry powder inhaler. 

With direct-to-lung delivery and improved pharmacokinetic properties, Tacrolimus Inhalation Powder has the potential to improve outcomes after lung transplantation.

In an open label, single arm, Phase 2 study of 14 lung transplant patients, Tacrolimus Inhalation Powder prevented acute rejection, decreased the expression of rejection related gene sets, prevented formation of donor-specific antibodies, and maintained renal function.

Tacrolimus Inhalation Powder has been granted orphan drug designation..